Altimmune registers Phase 3 pemvidutide trial in MASH under "PERFORMA" nameAug 31Trial updateAltimmune, Inc.pemvidutide
Altimmune reports Q2 2026 results as pemvidutide advances in MASH, AUD and ALDAug 12Quarterly updateAltimmune, Inc.pemvidutide
Sign inSign in